Compositions of R(+) and S(−) pramipexole and methods of using the same
Compositions of predetermined amounts of R(+) pramipexole and S(−) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided.
1. A method of treating Parkinson's disease or the symptoms thereof comprising administering a solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole, wherein said therapeutically effective amount of R(+) pramipexole is from 100 milligrams to 3,000 milligrams and said amount of S(−) pramipexole is from 1.5 milligrams to 4.5 milligrams.
2. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is from 300 milligrams to 1,500 milligrams.
3. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is from 500 milligrams to 1,000 milligrams.
4. The method of claim 1 , wherein said solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is administered from one to five times a day.
5. The method of claim 1 , wherein said solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is administered three times a day.
6. The method of claim 1 , wherein said solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is a single pharmaceutical composition.
7. The method of claim 1 , wherein said solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is more than one pharmaceutical composition.
8. The method of claim 1 , wherein said solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is administered once a day.
9. The method of claim 1 , wherein said solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is administered two times a day.
10. The method of claim 1 , wherein said solid unit dose is selected from a tablet, a capsule, a lozenge, a pellet, a granule, a bead, a cachet, an implant, a suppository, a pessary, and a powder.
11. The method of claim 1 , wherein said solid unit dose is a pharmaceutical composition selected from an immediate release pharmaceutical composition and a sustained release pharmaceutical composition.
12. A method of treating Parkinson's disease or the symptoms thereof comprising orally administering a unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole, wherein said therapeutically effective amount of R(+) pramipexole is from 100 milligrams to 3,000 milligrams and said amount of S(−) pramipexole is from 1.5 milligrams to 4.5 milligrams.
13. The method of claim 12 , wherein said therapeutically effective amount of R(+) pramipexole is from 300 milligrams to 1,500 milligrams.
14. The method of claim 12 , wherein said therapeutically effective amount of R(+) pramipexole is from 500 milligrams to 1,000 milligrams.
15. The method of claim 12 , wherein said unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is administered from one to five times a day.
16. The method of claim 12 , wherein said unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is administered three times a day.
17. The method of claim 12 , wherein said unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is a single pharmaceutical composition.
18. The method of claim 12 , wherein said unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is more than one pharmaceutical composition.
19. The method of claim 12 , wherein said unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is administered once a day.
20. The method of claim 12 , wherein said unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is administered two times a day.
21. The method of claim 12 , wherein said unit dose is selected from a tablet, a capsule, a lozenge, a pellet, a granule, a bead, a cachet, a powder, and a liquid.
22. The method of claim 12 , wherein said unit dose is a pharmaceutical composition selected from an immediate release pharmaceutical composition and a sustained release pharmaceutical composition.
23. A method of treating Parkinson's disease or the symptoms thereof comprising administering a solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole, wherein said therapeutically effective amount of R(+) pramipexole is from 100 milligrams to 3,000 milligrams and said amount of S(−) pramipexole is 4.5 milligrams.
24. The method of claim 23 , wherein said therapeutically effective amount of R(+) pramipexole is from 300 milligrams to 1,500 milligrams.
25. The method of claim 23 , wherein said therapeutically effective amount of R(+) pramipexole is from 500 milligrams to 1,000 milligrams.
26. The method of claim 23 , wherein said solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is a single pharmaceutical composition.
27. The method of claim 23 , wherein said solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is more than one pharmaceutical composition.
28. The method of claim 23 , wherein said solid unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is administered once a day.
29. The method of claim 23 , wherein said solid unit dose is selected from a tablet, a capsule, a lozenge, a pellet, a granule, a bead, a cachet, an implant, a suppository, a pessary, and a powder.
30. The method of claim 23 , wherein said solid unit dose is a pharmaceutical composition selected from an immediate release pharmaceutical composition and a sustained release pharmaceutical composition.
31. A method of treating Parkinson's disease or the symptoms thereof comprising orally administering a unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole, wherein said therapeutically effective amount of R(+) pramipexole is from 100 milligrams to 3,000 milligrams and said amount of S(−) pramipexole is 4.5 milligrams.
32. The method of claim 31 , wherein said therapeutically effective amount of R(+) pramipexole is from 300 milligrams to 1,500 milligrams.
33. The method of claim 31 , wherein said therapeutically effective amount of R(+) pramipexole is from 500 milligrams to 1,000 milligrams.
34. The method of claim 31 , wherein said unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is a single pharmaceutical composition.
35. The method of claim 31 , wherein said unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is more than one pharmaceutical composition.
36. The method of claim 31 , wherein said unit dose of a therapeutically effective amount of R(+) pramipexole and an amount of S(−) pramipexole is administered once a day.
37. The method of claim 31 , wherein said unit dose is selected from a tablet, a capsule, a lozenge, a pellet, a granule, a bead, a cachet, a powder, and a liquid.
38. The method of claim 31 , wherein said unit dose is a pharmaceutical composition selected from an immediate release pharmaceutical composition and a sustained release pharmaceutical composition.
39. The method of claim 1 , wherein said solid unit dose is administered in a route selected from orally, topically, sublingually, bucally, intravaginally, and rectally.
40. The method of claim 23 , wherein said solid unit dose is administered in a route selected from orally, topically, sublingually bucally, intravaginally, and rectally.
41. The method of claim 1 , wherein said amount of S(−) pramipexole is 1.5 milligrams.
42. The method of claim 12 , wherein said amount of S(−) pramipexole is 1.5 milligrams.